All articles tagged with #eli lilly
Eli Lilly’s experimental triple-agonist retatrutide achieved up to 25% weight loss in non-diabetic adults and 18.8% in those with type 2 diabetes in Phase 3 trials. The drug targets GLP-1, GIP, and glucagon, offering benefits beyond weight loss, including improved knee pain, sleep apnea, and blood sugar control, though gastrointestinal side effects remain common.
Eli Lilly and Novo Nordisk are advancing next-generation obesity treatments targeting the amylin pathway and multiple hormone receptors. Lilly’s Phase 2 trial showed its amylin drug eloralintide, combined with tirzepatide, achieved 23.3% weight loss, though side effects caused higher discontinuation rates. Meanwhile, Lilly’s triple-agonist retatrutide reached a Phase 3 milestone, with 12mg doses yielding 18.8% weight loss and improved metabolic markers in diabetic patients. Novo is preparing to launch its amylin-based CagriSema next year. These developments aim to address patients who do not respond adequately to current GLP-1 therapies, expanding treatment options through multi-pathway approaches.
Foghorn Therapeutics is terminating its collaboration with Eli Lilly and cutting 40% of its workforce after the lead candidate, FHD-909, failed to show sufficient efficacy in Phase 1 trials. The company will pivot to its proprietary pipeline, including EP300 and CBP degraders, while retaining $167.6 million in cash to fund operations through late 2029.
Eli Lilly has released new Phase 3 data for its triple-agonist drug retatrutide, showing that even the lowest dose yields significant weight loss, while a new combination therapy, EloraTZP, demonstrates even greater efficacy but with higher dropout rates due to side effects.
Eli Lilly reported that its experimental triple-agonist retatrutide caused an average weight loss of 49.6 pounds in patients with Type 2 diabetes, while a new combination therapy, EloraTZP, achieved up to 54.1 pounds of loss. Both drugs target multiple gut hormones to enhance satiety and metabolic control, with retatrutide expected to seek FDA approval by March 2027.
Eli Lilly reported that its experimental combination therapy, eloraTZP, achieved an average weight loss of 23.3% in patients with obesity and type 2 diabetes, surpassing its own triple-agonist candidate retatrutide in that specific population. The Phase 2 trial, presented at the European Association for the Study of Diabetes in Milan, showed that the highest dose of the amylin and tirzepatide combo resulted in a 54.1-pound loss over 48 weeks. While efficacy was strong, discontinuation rates due to gastrointestinal side effects were higher than for individual components. Lilly plans to begin Phase 3 trials in the fourth quarter of 2026, aiming to optimize dosing to improve tolerability while maintaining efficacy.
Eli Lilly has advanced two major obesity treatments: a new amylin-tirzepatide combination and the triple-agonist retatrutide. The combination therapy achieved up to 23.3% weight loss in a Phase 2 trial, while retatrutide reached up to 25% weight loss in Phase 3 trials for obesity and 23% for Type 2 diabetes. Both drugs target multiple gut hormones to enhance satiety and metabolic effects, positioning them as potential alternatives to existing GLP-1 therapies. Lilly plans to file for retatrutide approval early next year and advance the combination therapy to Phase 3 trials by late 2026.
Eli Lilly presented detailed phase 3 data for retatrutide and phase 2 results for the experimental combination EloraTZP at the European Association for the Study of Diabetes in Milan. Retatrutide, a triple-agonist, achieved 20.8% average weight loss at the top dose, while EloraTZP, combining amylin and tirzepatide, reached 23.3% weight loss. Lilly plans to file for retatrutide approval in early 2027 and advance EloraTZP to phase 3 trials by year-end.
Eli Lilly reported that its experimental combination of the amylin-targeting drug eloralintide and its existing GLP-1/GIP drug tirzepatide produced superior weight loss in a mid-stage trial. Patients with obesity and Type 2 diabetes lost up to 23.3% of their body weight over 48 weeks, outperforming tirzepatide alone. While the results are promising, higher discontinuation rates due to side effects raised questions about tolerability. Lilly plans to advance the therapy to Phase 3 trials by the end of 2026.
Eli Lilly’s experimental triple-agonist drug retatrutide has demonstrated unprecedented weight-loss results in two major Phase 3 trials, with participants losing up to 25% of their body weight. The drug, which targets three gut hormones, also significantly improved blood sugar control and cardiometabolic markers, though it carries gastrointestinal side effects similar to existing GLP-1 medications.
Eli Lilly’s experimental triple-agonist retatrutide achieved record-breaking weight loss in two phase 3 trials, with participants losing up to 25% of body weight. The drug also improved cardiometabolic markers and resolved prediabetes in over 90% of cases, though it carries gastrointestinal side effects and lacks head-to-head comparisons with existing treatments.
Eli Lilly’s experimental triple-agonist drug, retatrutide, has demonstrated unprecedented weight loss in late-stage clinical trials. In a phase 3 study for patients with Type 2 diabetes, participants lost up to 23% of their body weight, while those with obesity but no diabetes lost up to 25%. The drug targets three hormones, including glucagon, to enhance metabolic effects beyond existing GLP-1 therapies. Lilly plans to file for FDA approval early next year, though unapproved versions are already circulating.
Eli Lilly’s sponsorship of Vogue World: Milano has triggered sharp criticism from health experts and charities, who argue the partnership normalizes medical weight loss as a beauty standard. While the event featured plus-size models, critics contend the association between a major pharmaceutical brand and high fashion reinforces harmful thinness ideals.
Novo Nordisk’s recent strategy presentation failed to reassure investors, as Eli Lilly continues to widen its market share advantage in obesity treatments. While Novo outlined a broad pipeline to replace its flagship drugs, Lilly’s commercial strength and new products are driving a significant shift in market dominance.
Hundreds of lawsuits allege that popular weight-loss drugs like Ozempic and Mounjaro cause NAION, a rare condition leading to permanent vision loss. While manufacturers deny causation, some countries have updated drug labels to include this risk, and the FDA is reviewing the evidence.